Established In 2012Medigen Vaccine Biologics Corpmvcis A Subsidiary Of Medigen Biotechnology Corpwww Medigen Com Tw Taipeitaiwanmvc Develops Vaccines And Biosimilars For Important Unmet Medical Needsour Focus Is To Deliver Affordable Medicines For Developing Countries And With A Particular Focus On Se Asiawe Aim To Become One Of The Leading Pharmaceutical Companies For Taiwan And Global Communitieshumanityinnovationand Quality Are Mvc Core Valueswe Integrate Biomedical Technologies To Improve Human Health So That Every Personfrom Infants To Seniorshas A Chance To Be Free From Infectious Diseases Our Most Advanced Products Are Mvc 1901 And Mvc Eva71Mvc 1901 Is A Spike Protein Based Subunit Vaccine For Covid 19 Based On A Very Large Phase 2 Trial Powered To Assess Safety And Efficacy By Immunobridgingthe Vaccine Has Eua Status In Taiwanphase 3 Trials For Full Approval Are In Progress Mvc Evc71A Is An Inactivated Whole Virus Based Vaccine For Enteroviral Disease In Children Between 2 Months And 12 Years Of Agethe Vaccine Has Recently Completed A Phase 3 Trial And Is Currently In Regulatory Review For Commercial Licensing
